

Sanjay Popat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8180337/publications.pdf>

Version: 2024-02-01

326
papers

14,957
citations

66315

42
h-index

20943

115
g-index

340
all docs

340
docs citations

340
times ranked

15631
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Targetable Pathwaysâ€”ALK. , 2022, , 853-864.		0
2	Molecular Targetable Pathways â€” EGFR. , 2022, , 844-852.		0
3	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon <i>EGFR</i> Mutations: A Retrospective International Cohort Study (UpSwinG). <i>Oncologist</i> , 2022, 27, 255-265.	1.9	13
4	Targeting un-MET needs in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 164, 56-68.	0.9	15
5	Lung Cancer in the United Kingdom. <i>Journal of Thoracic Oncology</i> , 2022, 17, 186-193.	0.5	7
6	A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. <i>Lung Cancer</i> , 2022, 165, 34-42.	0.9	20
7	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligenceâ€”Enabled Studies of Acute Phosphoproteomic Changes. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1020-1029.	1.9	3
8	Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idyllaâ„¢ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib. <i>European Journal of Cancer</i> , 2022, 166, 38-40.	1.3	6
9	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	0.9	9
10	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report. <i>Frontiers in Oncology</i> , 2022, 12, 834704.	1.3	15
11	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 758-767.	5.1	49
12	Indirect comparisons of brigatinib and alectinib for front-line <i>ALK</i>-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 2499-2510.	1.1	2
13	A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9â€”15 PROMISE-meso phase III trial. <i>Lung Cancer</i> , 2022, 169, 77-83.	0.9	1
14	AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with <i>RET</i> fusionâ€”positive advanced/metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9159-TPS9159.	0.8	0
15	Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	28
16	Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive <i>ALK+</i> NSCLC in ALTA-1L.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9072-9072.	0.8	0
17	Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. <i>European Journal of Cancer</i> , 2022, 171, 44-54.	1.3	14
18	[¹⁸ F]Fluorothymidine (FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3070-3070.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. <i>Current Medical Research and Opinion</i> , 2022, 38, 1587-1593.	0.9	2
20	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2021, 16, 764-773.	0.5	128
21	Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach. <i>Oncologist</i> , 2021, 26, e306-e315.	1.9	24
22	Mucinous adenocarcinoma arising in congenital pulmonary airway malformation: clinicopathological analysis of 37 cases. <i>Histopathology</i> , 2021, 78, 434-444.	1.6	16
23	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 397, 375-386.	6.3	638
24	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100114.	0.6	11
25	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naïve ALK+ non-small cell lung cancer (ALTA-1L). <i>Lung Cancer</i> , 2021, 155, 68-77.	0.9	12
26	Y disruption, autosomal hypomethylation and poor male lung cancer survival. <i>Scientific Reports</i> , 2021, 11, 12453.	1.6	15
27	Biomarker Testing for People With Advanced Lung Cancer in England. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100176.	0.6	8
28	Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma. <i>Drugs</i> , 2021, 81, 971-984.	4.9	5
29	Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. <i>Lung Cancer</i> , 2021, 156, 147-150.	0.9	4
30	An audit of compliance with NOLCP in the GLH era. <i>Lung Cancer</i> , 2021, 156, S27.	0.9	0
31	HER3 expression and MEK activation in non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , 2021, 10, LMT48.	1.5	7
32	Detection of tier 1 variants with circulating tumour (ct) DNA next generation sequencing (NGS) in UK non-small cell lung cancer (NSCLC) patients. <i>Lung Cancer</i> , 2021, 156, S28.	0.9	0
33	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 9-16.	0.9	7
34	Brain metastases in solid tumours: new guidelines for a new era. <i>Annals of Oncology</i> , 2021, 32, 1322-1324.	0.6	2
35	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). <i>Future Oncology</i> , 2021, 17, 4237-4247.	1.1	11
36	Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score 2: Systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 158, 97-106.	0.9	31

#	ARTICLE	IF	CITATIONS
37	Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). <i>Lung Cancer</i> , 2021, 162, 9-15.	0.9	18
38	Brigatinib Versus Crizotinib in ALK Inhibitor-“Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.	0.5	156
39	Integrated genomics point to immune vulnerabilities in pleural mesothelioma. <i>Scientific Reports</i> , 2021, 11, 19138.	1.6	12
40	Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. <i>British Journal of Cancer</i> , 2021, 125, 1210-1216.	2.9	10
41	Grading in Lung Adenocarcinoma: Another New Normal. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1601-1604.	0.5	8
42	Pleural mesothelioma (PM) – The status of systemic therapy. <i>Cancer Treatment Reviews</i> , 2021, 100, 102265.	3.4	6
43	Durable Response to Vismodegib in PTCH1 F1147fs Mutant Relapsed Malignant Pleural Mesothelioma: Implications for Mesothelioma Drug Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 39-43.	1.5	6
44	Early response to chemotherapy in malignant pleural mesothelioma assessed using diffusion-weighted MRI: Initial observations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100253.	0.6	0
45	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 22-27.	0.9	22
46	Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting. <i>American Journal of Surgical Pathology</i> , 2020, 44, 347-356.	2.1	25
47	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 416-425.	0.5	17
48	A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. <i>Annals of Oncology</i> , 2020, 31, 1734-1745.	0.6	163
49	1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience. <i>Annals of Oncology</i> , 2020, 31, S1020-S1021.	0.6	1
50	Genomic testing in lung cancer: NGS and single gene testing-our experience as a genomics laboratory hub. <i>Lung Cancer</i> , 2020, 139, S63.	0.9	0
51	The National Lung Matrix Trial of personalized therapy in lung cancer. <i>Nature</i> , 2020, 583, 807-812.	13.7	96
52	PD-L1 expression in pleomorphic lung carcinoma with STK11 mutations. <i>Lung Cancer</i> , 2020, 139, S58.	0.9	0
53	LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743. <i>Annals of Oncology</i> , 2020, 31, S1441.	0.6	9
54	1352P Circulating tumour (ct) DNA next generation sequencing (NGS) in advanced non-small cell lung cancer (mNSCLC): A UK single institution experience. <i>Annals of Oncology</i> , 2020, 31, S867.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-“Naive ALK-Positive Non-“Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.	0.8	224
56	Baseline Results of the West London lung cancer screening pilot study “ Impact of mobile scanners and dual risk model utilisation. <i>Lung Cancer</i> , 2020, 148, 12-19.	0.9	37
57	Lorlatinib Salvages Central Nervous System-“Only Relapse on Entrectinib in ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e142-e144.	0.5	4
58	HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours. <i>Lung Cancer</i> , 2020, 139, S92.	0.9	0
59	Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. <i>BMJ Open</i> , 2020, 10, e038892.	0.8	42
60	EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. <i>Journal of Thoracic Oncology</i> , 2020, 15, e162-e165.	0.5	17
61	Case of Fatal Immune-Related Skin Toxicity From Sequential Use of Osimertinib After Pembrolizumab: Lessons for Drug Sequencing in Never-Smoking Non-“Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 842-844.	1.4	11
62	1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2020, 31, S826-S827.	0.6	8
63	1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial. <i>Annals of Oncology</i> , 2020, 31, S840-S841.	0.6	2
64	1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L. <i>Annals of Oncology</i> , 2020, 31, S843-S844.	0.6	1
65	1305P Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L. <i>Annals of Oncology</i> , 2020, 31, S844.	0.6	0
66	1341P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations. <i>Annals of Oncology</i> , 2020, 31, S860-S861.	0.6	0
67	1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC). <i>Annals of Oncology</i> , 2020, 31, S866.	0.6	0
68	1354P Detection of EGFR T790M in EGFR activating mutation-positive advanced non-small cell lung cancer (NSCLC): Comparison between two assays on circulating tumour (ct)DNA. <i>Annals of Oncology</i> , 2020, 31, S868.	0.6	0
69	LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial. <i>Annals of Oncology</i> , 2020, 31, S1211.	0.6	18
70	395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations. <i>Annals of Oncology</i> , 2020, 31, S1396.	0.6	0
71	420TiP UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib. <i>Annals of Oncology</i> , 2020, 31, S1405-S1406.	0.6	0
72	Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. <i>BMC Cancer</i> , 2020, 20, 1210.	1.1	9

#	ARTICLE	IF	CITATIONS
73	Squamous Nonâ€“Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of Tmprss2-ERG Translocation With SOX2 Amplification. JCO Oncology Practice, 2020, 16, 695-697.	1.4	0
74	Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?. Lung Cancer, 2020, 144, 76-84.	0.9	29
75	Stage III non-small cell lung cancer: a UK national survey of practice. Lung Cancer, 2020, 139, S27.	0.9	0
76	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	2.9	51
77	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 895-904.	5.2	111
78	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology, 2020, 15, 914-947.	0.5	119
79	CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. European Journal of Cancer, 2020, 127, 160-172.	1.3	112
80	Molecular testing for patients with advanced lung cancer in England: real-world evidence from the National Lung Cancer Audit. Lung Cancer, 2020, 139, S62-S63.	0.9	0
81	Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Journal of Thoracic Oncology, 2020, 15, 803-815.	0.5	178
82	Durable response of multiple myeloma and nonâ€“small cell lung cancer with simultaneous, biologically targeted treatment. British Journal of Haematology, 2020, 189, e1-e3.	1.2	4
83	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. , 2020, 8, e000713.		8
84	Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2â€“tier nuclear grade. Histopathology, 2020, 77, 423-436.	1.6	9
85	PET-CT in thoracic oncology: strengths, weaknesses and future directions. Lung Cancer, 2020, 139, S16.	0.9	0
86	Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice. Clinical Oncology, 2020, 32, 527-536.	0.6	9
87	Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed or refractory malignant mesothelioma.. Journal of Clinical Oncology, 2020, 38, 9058-9058.	0.8	16
88	Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.. Journal of Clinical Oncology, 2020, 38, 9517-9517.	0.8	18
89	Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.. Journal of Clinical Oncology, 2020, 38, TPS1100-TPS1100.	0.8	16
90	AcceleRET Lung: A phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, TPS9633-TPS9633.	0.8	12

#	ARTICLE	IF	CITATIONS
91	First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial. , 2020, 74, .		1
92	Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience. Cancer Treatment and Research Communications, 2020, 25, 100261.	0.7	3
93	Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Seminars in Oncology, 2019, 46, 145-154.	0.8	14
94	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine, 2019, 7, 569-580.	5.2	117
95	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	5.1	418
96	Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L. Annals of Oncology, 2019, 30, vi83.	0.6	1
97	Early proactive referral identifies lung cancer patients with significant palliative care needs. Lung Cancer, 2019, 127, S87.	0.9	0
98	Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the Wolf in Sheep's Clothing. Journal of Thoracic Oncology, 2019, 14, 1689-1691.	0.5	7
99	Intratumoral heterogeneity in PD-L1 expression in pleomorphic lung carcinoma: implications for management of stage III disease. Lung Cancer, 2019, 127, S91.	0.9	0
100	National Optimal Lung Cancer Pathway implementation: can pathologists comply with turnaround times?. Lung Cancer, 2019, 127, S3-S4.	0.9	1
101	The ALK project: a real-world national network and database. Lung Cancer, 2019, 127, S31-S32.	0.9	1
102	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology, 2019, 30, 1321-1328.	0.6	842
103	Real-world outcomes with pembrolizumab in patients with treatment-naive advanced/metastatic NSCLC in the UK: multicentre retrospective observational study. Lung Cancer, 2019, 127, S33-S34.	0.9	0
104	Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. Lung Cancer, 2019, 134, 117-120.	0.9	20
105	Brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Annals of Oncology, 2019, 30, ii48.	0.6	1
106	Brigatinib experience on the ALK project. Annals of Oncology, 2019, 30, ii53.	0.6	0
107	Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma. Annals of Oncology, 2019, 30, ii1.	0.6	1
108	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. Future Oncology, 2019, 15, 1363-1383.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Hyperprogression with immunotherapy: Is it real?. <i>Cancer</i> , 2019, 125, 1218-1220.	2.0	17
110	S47â€¦Impact of number of sampling sites and specimen dimension on the performance of nuclear grade and growth patterns in predicting survival in epithelioid malignant pleural mesothelioma: a single institution review of 614 cases. , 2019, , .		0
111	P1.01-124 Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs Crizotinib in NSCLC (ALTA-1L). <i>Journal of Thoracic Oncology</i> , 2019, 14, S411-S412.	0.5	2
112	IBS23.02 Oncological Treatment of Omd in Daily Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2019, 14, S115.	0.5	0
113	MA12.02 Growth Patterns in Epithelioid Malignant Pleural Mesothelioma: A Clinicopathological Review of 614 Cases Over 15 Years. <i>Journal of Thoracic Oncology</i> , 2019, 14, S295-S296.	0.5	0
114	P2.06-02 Mesothelioma Stratified Therapy (MiST): A Phase IIA Umbrella Trial for Accelerating the Development of Precision Medicines. <i>Journal of Thoracic Oncology</i> , 2019, 14, S755-S756.	0.5	6
115	MA23.10 Low Number of Mutations and Frequent Co-Deletions of CDKN2A and IFN Type I Characterize Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S345.	0.5	2
116	MA23.11 Analysis of Immune Phenotype Composition in Malignant Pleural Mesothelioma (MPM) Using Bulk RNA Sequencing. <i>Journal of Thoracic Oncology</i> , 2019, 14, S345-S346.	0.5	0
117	A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma. <i>PLoS ONE</i> , 2019, 14, e0225509.	1.1	1
118	P2.14-60 Afatinib in EGFR Mutation-Positive NSCLC: Activity in Patients with Brain Metastases, and Impact on CNS Progression/Spread. <i>Journal of Thoracic Oncology</i> , 2019, 14, S855.	0.5	0
119	P1.04-63 Correlation of Mutations in TP53, CDKN2A and PIK3CA with VISTA Expression in Pleomorphic Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S465-S466.	0.5	0
120	P1.06-08 WDPM-Like but Not Cribriform as Secondary Growth Patterns Modify Survival in Epithelioid Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S480-S481.	0.5	0
121	PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2019, 14, S7.	0.5	3
122	P2.06-05 Multimodality Therapy Using Total Pleurectomy in Malignant Pleural Mesothelioma: Long-Term Outcomes in 150 Consecutive Cases. <i>Journal of Thoracic Oncology</i> , 2019, 14, S757.	0.5	2
123	MA05.01 Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S264-S265.	0.5	0
124	Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9026-9026.	0.8	4
125	Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9084-9084.	0.8	6
126	In whom could we diagnose second primary lung cancers â€œearlyâ€™?. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
127	Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 192-193.	13.9	47
128	143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7. <i>Journal of Thoracic Oncology</i> , 2018, 13, S84-S85.	0.5	8
129	Targeted Therapy With or Without Dose-intensified Radiotherapy in Oligoprogressive Disease in Oncogene Addicted Lung Tumours. <i>Clinical Oncology</i> , 2018, 30, e64-e65.	0.6	0
130	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. <i>Clinical Lung Cancer</i> , 2018, 19, 42-50.	1.1	6
131	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, 74-83.e11.	1.1	28
132	Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience. <i>Journal of Thoracic Oncology</i> , 2018, 13, 63-72.	0.5	21
133	149P Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction. <i>Journal of Thoracic Oncology</i> , 2018, 13, S89-S90.	0.5	2
134	HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours. <i>Lung Cancer</i> , 2018, 115, S86.	0.9	0
135	Phase I dose escalation of pembrolizumab given concurrently with palliative thoracic radiotherapy (RT) for NSCLC. <i>Annals of Oncology</i> , 2018, 29, viii530.	0.6	1
136	Retrospective analysis of outcomes in UK patients with advanced NSCLC and ROS1 rearrangement. <i>Lung Cancer</i> , 2018, 115, S44.	0.9	0
137	MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry. <i>Journal of Thoracic Oncology</i> , 2018, 13, S367.	0.5	5
138	KRAS Subtypes in non-small cell lung cancer (NSCLC) within Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1). <i>Lung Cancer</i> , 2018, 115, S6.	0.9	0
139	Afatinib dose intensity and clinical efficacy in advanced EGFR-mutated non-small cell lung cancer: UK multicentre real-life data. <i>Annals of Oncology</i> , 2018, 29, viii526.	0.6	1
140	Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. <i>Annals of Oncology</i> , 2018, 29, viii746.	0.6	2
141	Lactate dehydrogenase and neutrophil-lymphocyte ratio as clinical predictors of outcome to PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 115, S40.	0.9	0
142	P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy. <i>Journal of Thoracic Oncology</i> , 2018, 13, S588-S589.	0.5	0
143	PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, S186.	0.5	2
144	ES06.02 Integrating New Systemic Therapy into Trials in OMD. <i>Journal of Thoracic Oncology</i> , 2018, 13, S200.	0.5	0

#	ARTICLE	IF	CITATIONS
145	Less frequent monitoring of response in patients with advanced thoracic malignancies receiving palliative chemotherapy, does not adversely impact patient care. <i>Lung Cancer</i> , 2018, 115, S42-S43.	0.9	1
146	P2.06-41 Differentiating Sarcomatoid Mesothelioma from Pleomorphic Carcinoma and Chest Wall Sarcoma Using GATA-3/MUC4/BAP1 IHC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S758-S759.	0.5	0
147	PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L). <i>Journal of Thoracic Oncology</i> , 2018, 13, S184-S185.	0.5	2
148	Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. <i>Annals of Oncology</i> , 2018, 29, viii497.	0.6	12
149	MA21.03 Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S430.	0.5	0
150	Copy number variations in malignant pleural mesothelioma reveal novel regions of genomic imbalances. <i>Lung Cancer</i> , 2018, 115, S27.	0.9	0
151	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018, 3, e000408.	2.0	4
152	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	0.6	1,571
153	P06 Competing CNS or Systemic Progression Analysis for EGFR Mutation-Positive NSCLC Patients on Afatinib in LUX-Lung 3, 6, and 7. <i>Journal of Thoracic Oncology</i> , 2018, 13, S163.	0.5	0
154	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039.	13.9	691
155	Targeted next-generation sequencing of malignant pleural mesothelioma identifies recurrent NRAS oncogene mutations. <i>Lung Cancer</i> , 2018, 115, S26.	0.9	0
156	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. <i>Future Oncology</i> , 2018, 14, 2415-2431.	1.1	24
157	216PD Should radical surgery be performed in non-epithelioid malignant pleural mesothelioma?. <i>Journal of Thoracic Oncology</i> , 2018, 13, S130.	0.5	0
158	213O Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study. <i>Journal of Thoracic Oncology</i> , 2018, 13, S128.	0.5	2
159	Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8515-8515.	0.8	44
160	Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9010-9010.	0.8	40
161	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9072-9072.	0.8	5
162	Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8568-8568.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study.. Journal of Clinical Oncology, 2018, 36, 8566-8566.	0.8	0
164	Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. European Journal of Cancer, 2017, 75, 56-62.	1.3	5
165	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future Oncology, 2017, 13, 1159-1171.	1.1	17
166	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respiratory Medicine, 2017, 5, 435-444.	5.2	172
167	LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2017, 18, 589-593.	1.1	17
168	Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer. Lung Cancer, 2017, 111, 51-58.	0.9	15
169	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, 2017, 77, 813-827.	4.9	42
170	Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 201-216.	1.4	30
171	Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 595-606.	1.1	54
172	Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. Journal of Thoracic Oncology, 2017, 12, 12-14.	0.5	9
173	Endocrine manifestations of malignancy. Medicine, 2017, 45, 547-550.	0.2	0
174	Novel insights into mesothelioma biology and implications for therapy. Nature Reviews Cancer, 2017, 17, 475-488.	12.8	287
175	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung Cancer, 2017, 111, 6-11.	0.9	2
176	OA 03.02 Comprehensive Characterization of Thymic Epithelial Tumor Subtypes Through an Analysis of Somatic Mutations and Copy Number Alterations. Journal of Thoracic Oncology, 2017, 12, S1749.	0.5	0
177	COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European Journal of Cancer, 2017, 87, 75-83.	1.3	24
178	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1552-1560.	0.5	75
179	Lack of response to nivolumab in a patient with EGFR -mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Lung Cancer, 2017, 111, 65-68.	0.9	18
180	Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. European Journal of Cancer, 2017, 70, 12-21.	1.3	36

#	ARTICLE	IF	CITATIONS
181	Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. <i>Lung Cancer</i> , 2017, 104, 131-133.	0.9	7
182	First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner isâ€¦. <i>Clinical Oncology</i> , 2017, 29, e1-e4.	0.6	4
183	P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S2397.	0.5	3
184	OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1555.	0.5	0
185	PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-NaÃve Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1577.	0.5	0
186	MTE 09.02 Symptom Experiences and Symptom Clusters in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1640-S1641.	0.5	0
187	P3.12-003 Optimized Inhaler Therapy Is Superior to Supportive Care Alone for Dyspnea in Patients with Coexisting COPD and Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2314-S2315.	0.5	0
188	MA 09.09 Isotoxic Dose-Escalated Radiotherapy (RT) in Non-Small Cell Lung Cancer (NSCLC) with Deep Inspiration Breath Hold (DIBH). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1838.	0.5	0
189	MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1884.	0.5	3
190	Diagnostic EGFR testing with ctDNA versus tumour in patients with advanced non-small cell lung cancer (NSCLC): The Royal Marsden experience. <i>Annals of Oncology</i> , 2017, 28, ii34-ii35.	0.6	0
191	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. <i>PLoS ONE</i> , 2017, 12, e0186106.	1.1	14
192	Proactive referral to palliative care: Model of a new integrated palliative care and oncology service. <i>Annals of Oncology</i> , 2017, 28, v640.	0.6	2
193	Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial. <i>Annals of Oncology</i> , 2017, 28, ix74.	0.6	2
194	Do Statins Improve Survival in Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1497-1498.	0.8	4
195	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 3591-3600.	0.8	121
196	Targeting RET in Patients With <i>RET</i> -Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	0.8	277
197	Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naÃve patients (pts) with malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8506-8506.	0.8	1
198	Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8581-TPS8581.	0.8	14

#	ARTICLE	IF	CITATIONS
199	Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, TPS9098-TPS9098.	0.8	1
200	Abstract 2627: A study of dynamic changes in PD-L1 expression in KRAS mutant adenocarcinoma of the lung exposed to signal transduction inhibitors. , 2017, , .		0
201	Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers. Annals of Oncology, 2016, 27, vi22.	0.6	2
202	ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive, advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Annals of Oncology, 2016, 27, vi448.	0.6	2
203	Nintedanib Plus Docetaxel as Second-Line Therapy in Patients with Non-Small-Cell Lung Cancer (NSCLC): A Network Meta-Analysis vs. New Therapeutic Options. Value in Health, 2016, 19, A711-A712.	0.1	0
204	3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice. Lung Cancer, 2016, 91, S2.	0.9	1
205	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discovery, 2016, 6, 838-851.	7.7	222
206	47 Completion of the clinical audit cycle for delivery of molecular testing service for patients with non-small-cell lung cancer referred to the Royal Marsden. Lung Cancer, 2016, 91, S17.	0.9	0
207	72 The Royal Marsden NHS Foundation Trust experience of maintenance pemetrexed following first-line cisplatin/pemetrexed in advanced non-squamous lung cancer. Lung Cancer, 2016, 91, S26.	0.9	0
208	Management of lung cancer. Medicine, 2016, 44, 244-248.	0.2	2
209	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. European Journal of Cancer, 2016, 60, 26-39.	1.3	28
210	A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. European Journal of Cancer, 2016, 61, 102-110.	1.3	30
211	163 A randomised study comparing the effectiveness of acupuncture (A) or morphine (M) versus the combination (AM) for the relief of dyspnoea in patients with advanced non small cell lung cancer and mesothelioma. Lung Cancer, 2016, 91, S59.	0.9	0
212	P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, S216.	0.5	5
213	Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology, 2016, 90, 280-288.	0.9	7
214	Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. Journal of Thoracic Oncology, 2016, 11, 1627-1643.	0.5	67
215	141 HALT trial: stereotactic radiotherapy for oligo-progressive disease (OPD) in oncogene-addicted lung tumours - results of a national trial feasibility questionnaire. Lung Cancer, 2016, 91, S51.	0.9	2
216	A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1029-1039.	0.5	38

#	ARTICLE	IF	CITATIONS
217	Problems of variable biomarker evaluation in stratified medicine researchâ€”A case study of ERCC1 in non-small-cell lung cancer. <i>Lung Cancer</i> , 2016, 92, 1-7.	0.9	11
218	1 A comparative analysis of cancer hotspot mutation profiles in circulating tumour cells, circulating tumour DNA and matched primary lung tumour. <i>Lung Cancer</i> , 2016, 91, S1.	0.9	0
219	Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 815-825.	1.1	4
220	First-Line Afatinib versus Chemotherapy in Patients with Nonâ€”Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2016, 11, 380-390.	0.5	300
221	A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 375-383.	1.1	10
222	Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a â€”chemosensitiveâ€” relapse: A single-arm phase II study (EORTC-08061). <i>European Journal of Cancer</i> , 2016, 54, 35-39.	1.3	17
223	Abstract 2243: Characterization of PD-L1 expression on circulating tumor cells (CTCs) isolated with a label-free inertial microfluidic system from advanced non-small cell lung cancer patients (NSCLC pts). , 2016, , .		2
224	Simultaneous EGFR mutation detection and copy number assessment in circulating tumour DNA (ctDNA) to inform molecular methods of therapy resistance and plasma ctDNA content in lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23027-e23027.	0.8	1
225	Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8574-TPS8574.	0.8	2
226	Phase II study of AZD4547 in <i> FGFR</i> amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 154-154.	0.8	15
227	Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH).. <i>Journal of Clinical Oncology</i> , 2016, 34, e14048-e14048.	0.8	0
228	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20507-e20507.	0.8	1
229	Expression of PD-L1, PD-L2 and PD-1 in thymic epithelial tumours (TETs).. <i>Journal of Clinical Oncology</i> , 2016, 34, e20107-e20107.	0.8	0
230	TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9106-TPS9106.	0.8	0
231	Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. , 2016, , .		0
232	3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. <i>European Journal of Cancer</i> , 2015, 51, S626-S627.	1.3	0
233	Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment. <i>Cancer Treatment Communications</i> , 2015, 4, 86-88.	0.4	1
234	339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH). <i>European Journal of Cancer</i> , 2015, 51, S67.	1.3	0

#	ARTICLE	IF	CITATIONS
235	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. BMC Research Notes, 2015, 8, 688.	0.6	4
236	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. PLoS ONE, 2015, 10, e0139074.	1.1	50
237	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology, 2015, 11, 2175-2191.	1.1	5
238	83: A review of the first 10 months of screening selected patients for the ALK translocation using immunohistochemistry, and their subsequent treatment. Lung Cancer, 2015, 87, S32-S33.	0.9	0
239	76: Patterns of extra-cranial disease progression in epidermal growth factor receptor (EGFR) mutant metastatic non-small cell lung cancer (NSCLC) patients on a tyrosine kinase inhibitor (TKI). Lung Cancer, 2015, 87, S30.	0.9	3
240	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future Oncology, 2015, 11, 409-420.	1.1	34
241	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	5.1	1,369
242	Research priorities in mesothelioma: A James Lind Alliance Priority Setting Partnership. Lung Cancer, 2015, 89, 175-180.	0.9	30
243	186: Forecasting patient recruitment for time-to-event analysis in National Lung Matrix Trial. Lung Cancer, 2015, 87, S69.	0.9	0
244	187: National Lung Matrix Trial: multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer. Lung Cancer, 2015, 87, S69-S70.	0.9	2
245	Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). European Journal of Cancer, 2015, 51, 1511-1528.	1.3	27
246	Never smoker with ground glass opacities on CT. Lancet Respiratory Medicine, the, 2015, 3, 328.	5.2	0
247	Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. BMC Cancer, 2015, 15, 163.	1.1	25
248	The efficacy of crizotinib in patients with <i>ALK</i>-positive nonsmall cell lung cancer. Therapeutic Advances in Respiratory Disease, 2015, 9, 97-104.	1.0	4
249	3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. European Journal of Cancer, 2015, 51, S711-S712.	1.3	24
250	Response evaluation in mesothelioma: Beyond RECIST. Lung Cancer, 2015, 90, 433-441.	0.9	25
251	Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Future Oncology, 2015, 11, 2525-2540.	1.1	25
252	Systemic therapy for pulmonary carcinoids. Lung Cancer, 2015, 90, 139-147.	0.9	16

#	ARTICLE	IF	CITATIONS
253	Phase II multicenter proof of concept study of AZD4547 in EGFR amplified tumours.. Journal of Clinical Oncology, 2015, 33, 2508-2508.	0.8	32
254	TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.. Journal of Clinical Oncology, 2015, 33, TPS8109-TPS8109.	0.8	1
255	Abstract 2408: A novel multiplex droplet digital PCR approach to KRAS mutation detection in circulating tumor DNA. , 2015, , .		0
256	A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer, 2014, 14, 674.	1.1	24
257	A Comparison of Immunohistochemical Assays and FISH in Detecting the ALK Translocation in Diagnostic Histological and Cytological Lung Tumor Material. Journal of Thoracic Oncology, 2014, 9, 769-774.	0.5	40
258	38 Patterns of relapse and detection method in patients with resected non-small cell lung cancer (NSCLC) – a single institution experience. Lung Cancer, 2014, 83, S15.	0.9	0
259	Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. European Journal of Cancer, 2014, 50, 1717-1721.	1.3	12
260	Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). International Journal of Radiation Oncology Biology Physics, 2014, 90, S5-S6.	0.4	2
261	Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 1254-1262.	5.1	95
262	Understanding lung cancer molecular subtypes. Clinical Practice (London, England), 2014, 11, 441-453.	0.1	2
263	13 Molecular profiling of non-small cell lung cancer (NSCLC) – the liquid biopsy comes of age. Lung Cancer, 2014, 83, S5.	0.9	0
264	47 The ability of a filter-based antibody-independent approach to capture circulating tumour cells for the diagnosis of lung cancer. Lung Cancer, 2014, 83, S17-S18.	0.9	0
265	8 The utility of peripheral blood circulating tumour cells for the detection of KRAS, EGFR and BRAF mutations in primary lung cancer. Lung Cancer, 2014, 83, S3-S4.	0.9	0
266	Afatinib in the treatment of EGFR mutation-positive NSCLC – A network meta-analysis. Lung Cancer, 2014, 85, 230-238.	0.9	47
267	Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmacogenomics and Personalized Medicine, 2014, 7, 285.	0.4	30
268	Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. Journal of Clinical Oncology, 2014, 32, TPS7612-TPS7612.	0.8	1
269	Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. Journal of Thoracic Disease, 2014, 6, 356-68.	0.6	1
270	A comparative study of blood-based KRAS mutation analysis in circulating tumor cells versus circulating plasma DNA to predict primary tumor mutations in lung cancer.. Journal of Clinical Oncology, 2014, 32, 7563-7563.	0.8	0

#	ARTICLE	IF	CITATIONS
271	Abstract 4657: Evaluation of genomic profiling in the GALAXY-1 (NCT01348126), a randomized Phase 2b study of ganetespib in combination with docetaxel versus docetaxel alone as second line therapy in patients with advanced NSCLC. <i>Cancer Research</i> , 2014, 74, 4657-4657.	0.4	1
272	Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?. <i>Annals of Palliative Medicine</i> , 2014, 3, 19-21.	0.5	5
273	Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma. <i>BMC Cancer</i> , 2013, 13, 207.	1.1	15
274	Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. <i>Lung Cancer</i> , 2013, 80, 1-4.	0.9	72
275	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). <i>European Journal of Cancer</i> , 2013, 49, 2815-2822.	1.3	45
276	Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. <i>Cancer</i> , 2013, 119, 2383-2390.	2.0	45
277	The role of afatinib in the management of non-small cell lung carcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1529-1539.	1.5	4
278	<i>EGFR</i> and <i>KRAS</i> mutations, and <i>ALK</i> fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2013, 14, 1765-1777.	0.6	38
279	Endocrine manifestations of "Amalgancy". <i>Medicine</i> , 2013, 41, 570-572.	0.2	0
280	A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations. <i>Lung Cancer</i> , 2013, 80, 339-340.	0.9	20
281	What exactly are we doing to improve low lung cancer survival in the United Kingdom?. <i>Thorax</i> , 2013, 68, 504-505.	2.7	3
282	A Pilot Study of a Novel Home Telemonitoring System for Oncology Patients Receiving Chemotherapy. <i>Journal of Telemedicine and Telecare</i> , 2013, 19, 148-152.	1.4	8
283	Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2013, 8, 783-787.	0.5	76
284	FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2626-TPS2626.	0.8	5
285	Platelet counts (PLT) at baseline and on treatment as predictor for progression free survival (PFS) in patients with advanced malignant pleural mesothelioma (MPM): EORTC 08052 study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7585-7585.	0.8	0
286	Establishing an EGFR mutation screening service for non-small cell lung cancer " Sample quality criteria and candidate histological predictors. <i>European Journal of Cancer</i> , 2012, 48, 61-67.	1.3	34
287	ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma. <i>Lung Cancer</i> , 2012, 75, 300-305.	0.9	52
288	True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 75, 133-135.	0.9	4

#	ARTICLE	IF	CITATIONS
289	Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report. <i>Medical Oncology</i> , 2012, 29, 2623-2625.	1.2	5
290	Management of lung cancer. <i>Medicine</i> , 2012, 40, 202-207.	0.2	0
291	Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1962-1963.	0.5	68
292	Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations. <i>PLoS ONE</i> , 2011, 6, e25164.	1.1	77
293	Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1397-1403.	0.5	20
294	Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 436-441.	0.5	196
295	Guidelines on the radical management of patients with lung cancer. <i>Thorax</i> , 2010, 65, iii1-iii27.	2.7	393
296	The combination of Young's syndrome and small cell lung cancer—A spiky connection?. <i>Lung Cancer</i> , 2010, 67, 372-375.	0.9	0
297	Supersensitive Mutation: Two Case Reports of Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , 2010, 11, E5-E8.	1.1	3
298	Endocrine manifestations of malignancy. <i>Medicine</i> , 2009, 37, 457-460.	0.2	0
299	Extraskeletal myxoid chondrosarcoma. <i>Cancer</i> , 2008, 113, 3364-3371.	2.0	272
300	Time Trends in the Outcome of Elderly Patients with Breast Cancer. <i>Breast Journal</i> , 2008, 14, 158-163.	0.4	8
301	Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 59, 227-231.	0.9	12
302	Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 324-335.	4.3	37
303	Good Vibrations and the Power of Positron Thinking: Positron Emission Tomography and Endoscopic Ultrasound in Staging of Mesothelioma—Two Case Reports. <i>Journal of Thoracic Oncology</i> , 2008, 3, 539-541.	0.5	0
304	Gut microflora associated characteristics in first-degree relatives of children with celiac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1204-1208.	0.6	31
305	Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival. <i>Journal of Thoracic Oncology</i> , 2007, 2, 735-740.	0.5	29
306	Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. <i>Lung Cancer</i> , 2007, 56, 135-137.	0.9	43

#	ARTICLE	IF	CITATIONS
307	Malignant pleural mesothelioma: Two cases in first degree relatives. <i>Lung Cancer</i> , 2007, 57, 407-409.	0.9	1
308	Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. <i>Anticancer Research</i> , 2007, 27, 627-33.	0.5	29
309	Palliative treatments for patients with inoperable gastroesophageal cancers. <i>International Journal of Palliative Nursing</i> , 2006, 12, 306-317.	0.2	3
310	Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. <i>BMC Cancer</i> , 2006, 6, 150.	1.1	20
311	Genetic Variants of UGT1A6 Influence Risk of Colorectal Adenoma Recurrence. <i>Clinical Cancer Research</i> , 2006, 12, 6585-6589.	3.2	40
312	Chemotherapy strategies in the treatment of small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2005, 16, 361-372.	0.7	14
313	Re: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). <i>Journal of the National Cancer Institute</i> , 2005, 97, 1855-1855.	3.0	9
314	Re: Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2005, 97, 858-858.	3.0	3
315	Relationship Between Thymidylate Synthase (TS) Genotype and TS Expression: A Tissue Microarray Analysis of Colorectal Cancers. <i>International Journal of Surgical Pathology</i> , 2005, 13, 127-133.	0.4	8
316	Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis. <i>Journal of Clinical Oncology</i> , 2005, 23, 609-618.	0.8	1,574
317	A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. <i>European Journal of Cancer</i> , 2005, 41, 2060-2070.	1.3	161
318	Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2004, 22, 529-536.	0.8	416
319	Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?. <i>Lung Cancer</i> , 2004, 43, 369-370.	0.9	6
320	Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer. <i>Cancer Genetics and Cytogenetics</i> , 2003, 145, 70-73.	1.0	9
321	Polymorphic sequence variants in medicine: a challenge and an opportunity. <i>Clinical Medicine</i> , 2003, 3, 260-264.	0.8	8
322	Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. <i>Carcinogenesis</i> , 2003, 25, 369-373.	1.3	30
323	Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. <i>Annals of Human Genetics</i> , 2002, 66, 125-37.	0.3	11
324	Germline mutations in TGM2 do not contribute to coeliac disease susceptibility in the Swedish population. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 1477-1479.	0.8	3

#	ARTICLE	IF	CITATIONS
325	Prevalence of the APC E1317Q variant in colorectal cancer patients. <i>Cancer Letters</i> , 2000, 149, 203-206.	3.2	41
326	Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. <i>Leukemia</i> , 1999, 13, 1497-1500.	3.3	34